Loading…
for educational and safety purposes
Amiodarone and Flecainide both come up in the same conversations; they overlap on Heart Rhythm. Amiodarone: Amiodarone is a potent antiarrhythmic drug used to treat and prevent serious disturbances of the heart rhythm, particularly life-threatening ventricular arrhythmias and atrial fibrillation. Flecainide: Flecainide is a prescription Class Ic antiarrhythmic best known for suppressing ventricular and supraventricular arrhythmias, but it is featured here through an unconventional cognition and neuroprotection lens rather than its approved cardiac indication.
Amiodarone is a potent antiarrhythmic drug used to treat and prevent serious disturbances of the heart rhythm, particularly life-threatening ventricular arrhythmias and atrial fibrillation. Although classified as a class III agent, it acts on all phases of the cardiac electrical cycle and has properties spanning several antiarrhythmic classes. It is highly effective but notable for an unusually long duration of action and a wide range of potential side effects affecting the lungs, thyroid, liver, eyes, and skin [1].
Flecainide is a prescription Class Ic antiarrhythmic best known for suppressing ventricular and supraventricular arrhythmias, but it is featured here through an unconventional cognition and neuroprotection lens rather than its approved cardiac indication. The scientific hook is that flecainide, in addition to blocking the cardiac sodium channel, directly stabilizes the ryanodine receptor RyR2 and suppresses pathological intracellular calcium leak; the same RyR2 calcium leak has been implicated in neuronal dysfunction, tau pathology, and cognitive impairment in Alzheimer's models and in heart failure associated cognitive decline. A separate line of work shows that sodium channel blockade with flecainide protects axons from degeneration in neuroinflammatory models, which is a distinct neuroprotective rationale. Some users additionally pair a low dose antiarrhythmic with stimulants used for focus, reasoning that stimulants raise heart rate and arrhythmia risk while flecainide has proven antiarrhythmic action; this pairing is a theoretical, off label rationale rather than an established protocol. It is essential to be clear that human cognitive enhancement evidence for flecainide is preclinical or theoretical, and that flecainide remains a potent cardiac drug with a documented proarrhythmic risk in people with structural heart disease.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
blocks
Blocker (Class Ic)
blocks
antagonist
blocks
modulates
Use dependent blocker
Stabilizer
Indirect reducer
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.